Verified sources.
Clear updates.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Eli Lilly & Co.’s diabetes drug Mounjaro Eli Lilly & Co. ’s blockbuster diabetes drug Mounjaro won US approval to reduce the risk of serious cardiovascular problems, broadening the medicine’s reach beyond controlling blood sugar and strengthening its position in the increasingly competitive market for GLP-1 drugs. The Food and Drug Administration cleared Mounjaro to lower cardiovascular risk in adults with type 2 diabetes and established heart disease, according to a statement from Lilly on Friday.
Missing media or need the complete publisher report? Open Bloomberg.com
Media link supplied by the Scoop Newsroom app.
The text below was supplied by the Scoop Newsroom app. Third-party reporting is attributed in the source panel.
No additional independently verified detail is available beyond the summary above. The original reporting remains linked in the source panel.
Breaking news moves fast. Follow @Will466513 on X for breaking news alerts. Follow on X →
Dated changes to this report are shown here as they are published.
Removed by Scoop Timeline eligibility policy
